| Combination of | |
|---|---|
| Atoltivimab | Monoclonal antibody |
| Maftivimab | Monoclonal antibody |
| Odesivimab | Monoclonal antibody |
| Clinical data | |
| Trade names | Inmazeb |
| Other names | REGN-EB3 |
| AHFS/Drugs.com | Monograph |
| License data | |
| Routes of administration | Intravenous |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| KEGG | |
Atoltivimab/maftivimab/odesivimab, sold under the brand name Inmazeb, is a fixed-dose combination of three monoclonal antibodies for the treatment of Zaire ebolavirus (Ebola virus).[2] It contains atoltivimab, maftivimab, and odesivimab-ebgn and was developed by Regeneron Pharmaceuticals.[2]
The most common side effects include fever, chills, tachycardia (fast heart rate), tachypnea (fast breathing), and vomiting; however, these are also common symptoms of Ebola virus infection.[2][3]
Atoltivimab/maftivimab/odesivimab is the first FDA-approved treatment for Zaire ebolavirus.[2] Atoltivimab/maftivimab/odesivimab was approved for medical use in the United States in October 2020.[2][4][5][3][6] The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.[7] It is on the World Health Organization's List of Essential Medicines.[8]
- ^ "Inmazeb- atoltivimab, maftivimab, and odesivimab-ebgn injection, solution". DailyMed. Retrieved 17 January 2021.
- ^ a b c d e f Cite error: The named reference
FDA PRwas invoked but never defined (see the help page). - ^ a b "Drug Trials Snapshots: Inmazeb". U.S. Food and Drug Administration. 14 October 2020. Retrieved 23 October 2020.
This article incorporates text from this source, which is in the public domain.
- ^ "Regeneron's Antibody Cocktail REGN-EB3 (Inmazeb) is First FDA-Approved Treatment for Ebola (Zaire Ebolavirus)". Regeneron Pharmaceuticals Inc. (Press release). 14 October 2020. Retrieved 14 October 2020.
- ^ "Inmazeb: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 15 October 2020.
- ^ "Drug Approval Package: Inmazeb". U.S. Food and Drug Administration. 12 November 2020. Retrieved 23 December 2020.
- ^ "New Drug Therapy Approvals 2020". U.S. Food and Drug Administration (FDA). 31 December 2020. Retrieved 17 January 2021.
- ^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
